Some patients with early-stage, low-risk breast cancer may not need radiation therapy after breast conserving surgery, according to new research from the UBC faculty of medicine, BC Cancer, McMaster University… Read More
Minjuvi® (tafasitamab) is the first CD19 targeted immunotherapy option for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), addressing a significant unmet medical need This is the first public listing since… Read More
Early Bird 50% Discount Before September 1, 2023 TORONTO ON — StarFish Medical announces the return of Medical Device Playbook to Toronto’s MaRS DD on October 19, 2023, from 9am to… Read More
Frontage Laboratories, Inc. and its wholly-owned subsidiary, Frontage Canada, Inc., completed the acquisition of Nucro-Technics Inc. and its affiliate Nucro-Technics Holdings, Inc. Nucro-Technics is a pharmaceutical contract research organization that conducts… Read More
SignalChem Announces Patients Enrollment in Clinical Trial of AXL Inhibitor SLC-391 in Combination with KEYTRUDA® (pembrolizumab) for Advanced or Metastatic Non-Small Cell Lung Cancer VANCOUVER, BC — SignalChem Lifesciences Corp. is… Read More
